170 related articles for article (PubMed ID: 35860593)
1. Daily Management of Patients on Multikinase Inhibitors' Treatment.
Colombo C; De Leo S; Trevisan M; Giancola N; Scaltrito A; Fugazzola L
Front Oncol; 2022; 12():903532. PubMed ID: 35860593
[TBL] [Abstract][Full Text] [Related]
2. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
[No Abstract] [Full Text] [Related]
3. Thyroid cancer and COVID-19: experience at one single thyroid disease referral center.
Prete A; Falcone M; Bottici V; Giani C; Tiseo G; Agate L; Matrone A; Cappagli V; Valerio L; Lorusso L; Minaldi E; Molinaro E; Elisei R
Endocrine; 2021 May; 72(2):332-339. PubMed ID: 33638758
[TBL] [Abstract][Full Text] [Related]
4. Multikinase Inhibitor Treatment in Thyroid Cancer.
Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
[TBL] [Abstract][Full Text] [Related]
5. The treatment landscape in thyroid cancer: a focus on cabozantinib.
Weitzman SP; Cabanillas ME
Cancer Manag Res; 2015; 7():265-78. PubMed ID: 26316818
[TBL] [Abstract][Full Text] [Related]
6. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
7. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
[No Abstract] [Full Text] [Related]
8. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
Jerkovich F; García Falcone MG; Pitoia F
Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
[TBL] [Abstract][Full Text] [Related]
9. Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study.
Masaki C; Sugino K; Tanizawa Y; Nakamura K; Okada Y; Cai Z; Okamoto T
Drugs Real World Outcomes; 2023 Mar; 10(1):145-158. PubMed ID: 36527599
[TBL] [Abstract][Full Text] [Related]
10. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Tsoli M; Alexandraki KI; Spei ME; Kaltsas GA; Daskalakis K
Horm Metab Res; 2020 Jan; 52(1):25-31. PubMed ID: 31665790
[TBL] [Abstract][Full Text] [Related]
12. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Porta C; Paglino C; Imarisio I; Canipari C; Chen K; Neary M; Duh MS
BMC Cancer; 2011 Mar; 11():105. PubMed ID: 21435216
[TBL] [Abstract][Full Text] [Related]
13. Advances in small molecule therapy for treating metastatic thyroid cancer.
Krajewska J; Gawlik T; Jarzab B
Expert Opin Pharmacother; 2017 Aug; 18(11):1049-1060. PubMed ID: 28602103
[TBL] [Abstract][Full Text] [Related]
14. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
Jerkovich F; Califano I; Bueno F; Carrera JM; Giglio R; Abelleira E; Pitoia F
Endocrine; 2020 Jul; 69(1):142-148. PubMed ID: 32253682
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer.
Feola T; Cozzolino A; Centello R; Pandozzi C; Tarsitano MG; Giannetta E
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357141
[TBL] [Abstract][Full Text] [Related]
16. Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review.
De Leo A; Di Simone E; Spano A; Puliani G; Petrone F
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885070
[TBL] [Abstract][Full Text] [Related]
17. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
[TBL] [Abstract][Full Text] [Related]
18. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
19. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
20. RET kinase inhibitors for
Vodopivec DM; Hu MI
Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]